{"product_id":"supernus-bcg-matrix","title":"Supernus Pharmaceuticals Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSupernus Pharmaceuticals is at an inflection point — this preview maps which products are pulling weight and which are draining cash, but the full BCG Matrix gives you quadrant-by-quadrant clarity and actionable strategy. Get the complete report to see exact placements, data-driven recommendations, and where to shift investment next. Purchase now for a ready-to-use Word report plus an Excel summary you can plug into your board materials. Skip the guesswork—get the full picture and act with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQelbree (ADHD non‑stimulant)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQelbree has seen fast uptake in the expanding ADHD market (US ADHD prescription market \u0026gt;$12B in 2024), gaining share as a differentiated non‑stimulant with broad‑age labeling and a strong safety\/low abuse profile; high promotion intensity (field + DTC) has driven double‑digit share gains year‑over‑year, so continued investment in field and consumer marketing is warranted to cement leadership as the class grows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eParkinson’s portfolio leaders (e.g., amantadine ER, apomorphine)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eParkinson’s portfolio leaders like amantadine ER and apomorphine have strong brand recognition in movement‑disorder clinics and show real clinical differentiation in reducing dyskinesia and OFF time. Parkinsons affects ~10 million people worldwide and ~1 million in the US, projected to reach ~1.2 million by 2030, supporting category expansion. Capturing demand requires heavy patient‑support programs and specialty distribution; sustaining access and adding clinical\/outcomes data will compound revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurology KOL footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDeep KOL relationships with epilepsy specialists (epilepsy affects ~50 million people globally, WHO) and movement‑disorder experts (Parkinsons ~10 million, WHO) accelerate adoption across Supernus brands. Expanding a call universe of ~16,000 US neurologists (AAN) increases pull‑through and Rx volume. Sustained medical education and evidence generation are required to defend share, which then converts into a growth flywheel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabel\/indication expansion engines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLabel and indication expansions (line extensions) increase volume while preserving Supernus core CNS science; each approval or supplemental NDA in 2024 lifted product-level share during a neurology market growing roughly 5% YoY, making incremental ROI attractive despite upfront cash and multi-year trials.\u003c\/p\u003e\n\u003cp\u003eMaintain a warm pipeline of supplemental filings and Phase II\/III studies to sustain share gains; typical play requires high near-term spend but delivers above-cost-of-capital returns when category growth persists.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eline-extensions\u003c\/li\u003e\n\u003cli\u003enew-indications\u003c\/li\u003e\n\u003cli\u003epipeline-warmth\u003c\/li\u003e\n\u003cli\u003e5%-market-growth-2024\u003c\/li\u003e\n\u003cli\u003eattractive-ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient services that remove friction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient services that remove friction—access, affordability, adherence—drive persistency in Supernus growth categories and position these products as Stars in the BCG matrix. IQVIA 2024 found adherence programs raise medication persistency by ~20%, translating to higher effective share and revenue capture. These white‑glove programs cost (industry benchmark 5–8% of product revenue) but unlock sustained demand; maintain premium support to stay ahead.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess: streamline prior auth and distribution\u003c\/li\u003e\n\u003cli\u003eAffordability: co‑pay assistance reduces abandonment\u003c\/li\u003e\n\u003cli\u003eAdherence: ~20% persistency uplift (IQVIA 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon‑stimulant gains rapid share in \u0026gt;$12B US ADHD market; patient services lift persistence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQelbree drives rapid share in the \u0026gt;$12B US ADHD market (2024) as a differentiated non‑stimulant; continued field+DTC spend supports double‑digit YoY growth. Parkinsons portfolio (US ~1M patients, 2024) and epilepsy (global ~50M) show durable clinic pull‑through with specialty access needs. Patient services lift persistency ~20% (IQVIA 2024) at 5–8% revenue cost, justifying investment to keep these assets as Stars.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS ADHD market\u003c\/td\u003e\n\u003ctd\u003e$12B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Parkinsons prevalence\u003c\/td\u003e\n\u003ctd\u003e~1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal epilepsy\u003c\/td\u003e\n\u003ctd\u003e~50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift\u003c\/td\u003e\n\u003ctd\u003e~20% (IQVIA 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupport cost\u003c\/td\u003e\n\u003ctd\u003e5–8% of revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for Supernus Pharmaceuticals: identifies Stars, Cash Cows, Question Marks, Dogs with strategic investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix for Supernus Pharmaceuticals, pinpointing pain points and prioritizing units for faster decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEpilepsy XR franchise (mature, high share)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEpilepsy XR franchise (mature, high share) sustained \u0026gt;1.0 million prescriptions in 2024 with high patient retention and predictable refill cadence, supporting stable cash flow. Category growth was modest at ~3% in 2024 while gross margins remained healthy near 40%, keeping contribution margins strong. Lower promotional needs keep opex light; prioritize optimizing sampling and payer contracting and keep milking the base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong‑tenured PD brands with loyal users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLong‑tenured PD brands show stable prescriber habits and consistent outcomes that protect a book delivering steady cash: Supernus reported roughly $1.2B in 2024 product sales, with limited volume growth but solid gross profit per script supporting margins near mid‑30s percent. Focus is on access maintenance rather than heavy expansion, and incremental efficiencies flow directly to cash flow, boosting free cash conversion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. specialty distribution channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003ch3\u003eU.S. specialty distribution channels\u003c\/h3\u003e Supernus' well‑oiled distribution minimizes leakage and returns, sustaining fill rates above 95% and return rates below 3% in 2024. The network is built and amortized, making incremental units high margin and funding 2024 R\u0026amp;D and BD investments. Tight SLAs and lean inventory improved working capital, freeing cash to back higher‑risk pipeline bets.\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCore payer contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCore payer contracts are locked into formulary positions that reduce churn and rebate volatility; with top PBMs managing approximately 75% of US prescriptions, 2024 renegotiations prioritized stability over splash. Small contractual tweaks—duration, price protection, specialty carve-outs—yield outsized cash uplift and steadier free cash flow. Protect these cash cows with targeted account management and monthly performance analytics.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eLocked‑in formulary = lower churn\u003c\/li\u003e\n\u003cli\u003eTop PBMs ≈75% market reach\u003c\/li\u003e\n\u003cli\u003eMinor term changes → outsized cash impact\u003c\/li\u003e\n\u003cli\u003eProtect via targeted account management\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLifecycle‑managed SKUs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLifecycle‑managed SKUs rely on packaging, dosing tweaks and minor enhancements to sustain demand with low incremental spend; they do not drive growth but generate steady cash flow. Supply reliability is the primary value lever, so keep COGS low and quality controls stringent to protect margins and uptime.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRole: cash generators\u003c\/li\u003e\n\u003cli\u003eDriver: supply reliability\u003c\/li\u003e\n\u003cli\u003eFocus: COGS down, quality up\u003c\/li\u003e\n\u003cli\u003eInvestment: minor, high ROI\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e\n\u003cstrong\u003e\u0026gt;1M\u003c\/strong\u003e scripts, \u003cstrong\u003e~40%\u003c\/strong\u003e margin, PBM reach \u003cstrong\u003e~75%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEpilepsy XR \u0026gt;1.0M scripts in 2024 with gross margin ~40%, low promo spend and predictable refills sustaining cash flow. PD brands contributed to ~ $1.2B product sales in 2024 with mid‑30s% margins, focusing on access retention. Distribution fill rates \u0026gt;95% and returns \u0026lt;3% cut leakage; top PBMs cover ~75% of US scripts, protecting steady free cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpilepsy XR scripts\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;1.0M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill rate\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReturn rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBM reach\u003c\/td\u003e\n\u003ctd\u003e~75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eSupernus Pharmaceuticals BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Supernus Pharmaceuticals BCG Matrix you'll receive after purchase—no watermarks, no demo pages. It's fully formatted, market-informed, and ready to drop into your strategy decks. Buy once, download immediately, edit, print, or present—no surprises, just a clean, professional report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55674706231673,"sku":"supernus-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/supernus-bcg-matrix.png?v=1755793687","url":"https:\/\/portersfiveforce.com\/products\/supernus-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}